ANPCF - ANGLE partners with AstraZeneca in groundbreaking oncology contract
(NewsDirect)
ANGLE PLC chief executive Andrew Newlandjoins Proactive's Stephen Gunnion with news the company hasentered a significant contract with AstraZeneca, marking its secondmajor collaboration with a large pharmaceutical company.
Newland, expressed enthusiasm about thisdevelopment, noting the contract's potential to expand ANGLE'sservices in oncology trials. The initial phase of the contract isvalued at £150,000, but it holds substantial potential due to thepossibility of implementing a new assay in numerous cancer trialsinvolving AstraZeneca. The scope of the collaboration includes thedevelopment of assays for examining proteins on cancer cells acrossmultiple trials, with potential earnings of £2,000 per time point inover 460 trials.
The contract alsoenables ANGLE to further validate and possibly expand its FDAapprovals, positioning it uniquely as a provider of comprehensivediagnostic solutions internationally.
Looking ahead, the successful execution of the contract couldlead to extensive financial gains for ANGLE PLC, ranging into the tensor even hundreds of millions of pounds, particularly asAstraZeneca's trials progress and its drugs approach commerciallaunch.
Contact Details
Proactive UKLtd
+44 20 7989 0813
Copyright (c) 2024 TheNewswire - All rights reserved.